China Resources Shuanghe (600062.SH): The subsidiary's levetiracetam tablets obtained approval for drug supplement application

On September 29, China Resources Shuanghe (600062.SH) announced that recently, China Resources Saike Pharmaceutical Co., Ltd. ("CR Saike"), a wholly-owned subsidiary of China Resources Shuanghe Pharmaceutical Co., Ltd., received the "Notice of Approval of Drug Supplement Application" (Notice No. 2021B03350) issued by the State Drug Administration.

Levetiracetam tablets are used for the treatment of partial seizures (with or without secondary generalized seizures) in adults and children with epilepsy in children over 4 years of age, and for the addition of generalized tonic-clonic seizures in adults and adolescents over 16 years of age.

As of the announcement date, CR SECCO has invested a total of RMB 2.51 million (unaudited) in the research and development of levetiracetam tablets (0.25g).

In the domestic market, according to the information on the website of the State Food and Drug Administration, there are 9 production enterprises of levetiracetam tablets that have been approved for listing in Chinese mainland. According to data from the intranet, the total sales volume (terminal price) of domestic levoethyl piracetam tablets in 2020 is 856 million yuan, of which the top 5 companies in terms of market share are 69.44% of Youshibi Pharmaceutical Company, 20.12% of Zhejiang Jingxin Pharmaceutical Co., Ltd., 8.72% of Zhejiang Puluo Kangyu Pharmaceutical Co., Ltd., 1.45% of Chongqing Shenghuaxi Pharmaceutical Co., Ltd., and 0.24% of Shenzhen Xinlitai Pharmaceutical Co., Ltd.

This article originated from Grand Gateway